HER2-directed antibodies, affibodies and nanobodies as drug-delivery vehicles in breast cancer with a specific focus on radioimmunotherapy and radioimmunoimaging

B. Altunay, A. Morgenroth, M. Beheshti, A. Vogg, N.C.L. Wong, H.H. Ting, H.J. Biersack, E. Stickeler, F.M. Mottaghy

Research output: Contribution to journalReview articleAcademicpeer-review

7 Citations (Web of Science)
Original languageEnglish
Pages (from-to)1371-1389
Number of pages19
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume48
Issue number5
Early online date12 Nov 2020
DOIs
Publication statusPublished - May 2021

Keywords

  • affibody
  • anti-her2 nanobody
  • antibody drug conjugate
  • emitting radiotherapeutic agent
  • her2
  • her2 receptor expression
  • immunotherapy
  • in-vivo
  • monoclonal-antibody
  • n-succinimidyl
  • nanobody
  • preclinical evaluation
  • residualizing label
  • single domain antibody
  • single-domain antibody
  • trastuzumab emtansine t-dm1
  • EMITTING RADIOTHERAPEUTIC AGENT
  • Affibody
  • MONOCLONAL-ANTIBODY
  • N-SUCCINIMIDYL
  • Antibody drug conjugate
  • Immunotherapy
  • TRASTUZUMAB EMTANSINE T-DM1
  • Nanobody
  • RESIDUALIZING LABEL
  • HER2 RECEPTOR EXPRESSION
  • SINGLE-DOMAIN ANTIBODY
  • Single domain antibody
  • ANTI-HER2 NANOBODY
  • IN-VIVO
  • HER2
  • PRECLINICAL EVALUATION

Cite this